Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Precancerous Gastric Lesions 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Breast Neoplasms 1Barrett Esophagus 1Atrophy 1

Interventions

Glutamine 2glutamic acid diethyl ester 1Sugars 1Sodium Selenite 1Sodium Chloride 1Saline Solution 1Paclitaxel 1Omeprazole 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Ketamine 1Glutamic Acid 1Duloxetine Hydrochloride 1Drug Therapy 1Doxorubicin 1Dexamethasone 1Cyclophosphamide 1Carboplatin 1Bortezomib 1Bevacizumab 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Peripheral Nervous System Diseases × Omeprazole × Clear all
NCT05680870 2025-09-09

The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients

Tanta University

Phase 3 Completed
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Peripheral Nervous System Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡